



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
08/803,321	02/21/97	MOURITSEN	S P58774US2

18M1/0421

JACOBSON PRICE HOLMAN & STERN
THE JENIFER BUILDING
400 7TH STREET NW
WASHINGTON DC 20004-2201

EXAMINER	
ART UNIT	PAPER NUMBER
1816	9

DATE MAILED: 04/21/97

This is a communication from the examiner in charge of your application.
COMMISSIONER OF PATENTS AND TRADEMARKS

OFFICE ACTION SUMMARY

☒ Responsive to communication(s) filed on 2/21/97

☒ This action is FINAL.

☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 D.C. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

Disposition of Claims

- ☒ Claim(s) 1-12 is/are pending in the application.
Of the above, claim(s) _____ is/are withdrawn from consideration.
- ☐ Claim(s) _____ is/are allowed.
- ☒ Claim(s) 1-12 is/are rejected.
- ☐ Claim(s) _____ is/are objected to.
- ☐ Claim(s) _____ are subject to restriction or election requirement.

Application Papers

- ☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.
- ☐ The drawing(s) filed on _____ is/are objected to by the Examiner.
- ☐ The proposed drawing correction, filed on _____ is ☐ approved ☐ disapproved.
- ☐ The specification is objected to by the Examiner.
- ☒ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. § 119

☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

- ☐ All ☐ Some* ☒ None of the CERTIFIED copies of the priority documents have been
- ☐ received.
- ☐ received in Application No. (Series Code/Serial Number) _____
- ☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

*Certified copies not received: _____

☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e).

Attachment(s)

- ☐ Notice of Reference Cited, PTO-892
- ☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). _____
- ☐ Interview Summary, PTO-413
- ☐ Notice of Draftsperson's Patent Drawing Review, PTO-948
- ☐ Notice of Informal Patent Application, PTO-152

--SEE OFFICE ACTION ON THE FOLLOWING PAGES--

Art Unit 1816

15. Claims 1-12 are under consideration.

16. Drawings have been submitted which fail to comply with 37 CFR 1.84. Please see the form PTO-948 enclosed with paper no. 6.

17. This application contains sequence disclosures (eg. on pages 11,12 and 14) that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). In no case may an applicant extend the period for response beyond the SIX MONTH statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

18. The oath or declaration is defective. A new oath or declaration in compliance with 37 CFR-1.67(a) identifying this application by application number and filing date is required. See MPEP §§ 602.01 and 602.02.

The oath or declaration is defective because:

The declaration in the instant application needs to claim priority to PCT/DK94/00318 under 35 U.S.C. § 120 because said application is a CIP of PCT/DK94/00318.

19. Claims 1-12 remain rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for the reasons elaborated in the previous Office Action.

The specification does not disclose how to use the claimed method or autovaccine for the treatment of disease in vivo in humans. The claimed autovaccines read on autovaccines for the treatment of human disease. Regarding the claimed method, the specification has not enabled the

breadth of the claimed invention in view of the teachings of the specification because the use for the instant invention disclosed in specification is the treatment of disease in vivo in humans. The state of the art is such that is unpredictable from the in vivo mouse data disclosed in the specification as to whether the claimed inventions could be used for the treatment of human disease.

Regarding the mouse data disclosed in the specification, Osband et al. teaches that there exists a lack of useful animal models that can be applied to immunotherapy. Osband et al. further teach that animal models are not generally predictive of therapeutic efficacy in humans as relates to immunotherapy regimens (see page 193 in particular).

Regarding the use of peptides or proteins for therapeutic purposes (which are encompassed by the claimed method as disclosed in the specification), pharmaceutical therapies in the absence of appropriate in vivo or in vitro data establishing that said peptides can be used for the treatment of humans are unpredictable for the following reasons; (1) the peptide/protein may be inactivated before producing an effect, i.e. such as proteolytic degradation, immunological inactivation or due to an inherently short half-life of the protein/peptide; (2) the peptide/protein may not reach the target area because, i.e. the protein/protein may not be able to cross the mucosa or the protein may be adsorbed by fluids, cells and tissues where the protein/peptide has no effect; and (3) other functional properties, known or unknown, may make the peptide/protein unsuitable for in vivo therapeutic use, i.e. such as adverse side effects prohibitive to the use of such treatment. See page 1338, footnote 7 of Ex parte Aggarwal, 23 USPQ2d 1334 (PTO Bd. Pat. App. and Inter. 1992).

There is no disclosure in the specification of an actual autovaccine suitable for the treatment of human disease or guidance as to how such an autovaccine would be made. Regarding page 18 of the specification, there is no guidance in the specification as how a human TNFalpha autovaccine would be made. There is no guidance in the specification as to where T cell epitopes could be inserted in human TNFalpha without disrupting the overall tertiary structure. There is no guidance in the specification as to what dosage of any particular agent needs to be administered in order to treat any particular human disease or guidance as to how such a dosage would be established. It appears that undue experimentation would be required of one skilled in the art to practice the instant invention using the teaching of the specification. See Ex parte Forman, 230 USPQ 546, BPAI, 1986.

20. Claims 1-12 remain rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention for the reasons elaborated in the previous Office Action.

Claim 1 is indefinite in the recitation of "modulation of self-proteins" because it is unclear what this means or encompasses. Claim 1 is indefinite in the recitation of "modulated self-protein" because it is unclear what this means or encompasses and it lacks antecedent basis within the claim. Claim 1 is indefinite in the recitation of "providing a self-portion by molecular biological means" because it is unclear what this means or encompasses. Claim 2 is indefinite in the recitation of "preserve flanking regions" because it is unclear what this means or encompasses. Claim 6 is indefinite in the recitation of "modulated" because it is unclear what this means or encompasses. Claim 8 is indefinite in the recitation of "e.g. cancer patients" because it is unclear what this means or encompasses. Claim 11 is substantially duplicative of claim 10 because the recitation of an intended use carries no patentable weight in this product claim and therefore the two claims read on the same product.

21. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: ,

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

22. Claims 1-7,9 remain rejected under 35 U.S.C. 103(a) as being unpatentable over Lowenadler et al. in view of Berzofsky et al., Hellman (WO 93/05810) and Etlinger for the reasons elaborated in the previous Office Action..

The claims are drawn to a method for the modulation of self proteins. Lowenadler et al. teach that a T helper cell epitope of 16 amino acids can be inserted into a chimeric protein and induce an increased antibody response against the chimeric protein (see abstract). Lowenadler et al. teaches that the T helper cell epitope is inserted in a location that would be expected to preserve the tertiary structure of the chimeric protein (eg. see Figure 1). Berzofsky et al. teach

that most antibodies against intact proteins bind conformational epitopes that are determined by the three dimensional structure induced by the tertiary structure of said protein (see page 177). Therefore, a routineer would have inserted the T cell epitope in such a manner as to not disturb the tertiary structure of the protein. The construct taught by Lowenadler et al. is made by molecular biologic means and has at least 4 amino acids of the original protein on either side of the T cell epitope (see page 1186). Lowenadler et al. do not teach that this procedure is specifically used for modulation of self proteins. Hellman teaches that modulation of self proteins can be achieved using self-protein conjugated to a carrier which is recognized by T helper cells wherein the self protein is IgE (see pages 5-12). Hellman teaches that it is desirable to modulate the presence of IgE in patients that suffer from allergies (see abstract). Hellman teaches that the autovaccine (self-protein conjugated to a carrier which is recognized by T helper cells) can contain an adjuvant (page 11, second paragraph). A routineer would have used any art known adjuvant suitable for human administration. A routineer would have added any art cytokine which could boost the immune response to the autovaccine. Etlinger et al. teach that T cell epitopes derived from tetanus toxoid can be used to increase antibody response against a molecule to which said epitopes are conjugated (see Abstract). It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because Lowenadler et al. teach that by inserting T helper epitope(s) into a chimeric protein that increased antibody responses against different epitopes of the protein can be obtained. Furthermore, Lowenadler et al. shows that by increasing the number of copies of the T cell epitope placed into the chimeric protein and maximizing the location that increased antibody responses against multiple epitopes on the same chimeric protein can be achieved (see Table 1 and 1187-1188). A routineer would have used tetanus toxoid protein in the conjugate because Etlinger et al. teach the desirability of using molecules recognized by T cells that individuals would have already been vaccinated against (eg. tetanus toxoid).

23. Claims 8,10-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lowenadler et al. in view of Berzofsky et al., Hellman (WO 93/05810) and Etlinger as applied to claims 1-7,9 above, and further in view of prior art disclosed in the specification (page 18, last paragraph).

The claims are drawn to autovaccines containing TNF α . Paragraph 23 makes obvious

the instant invention except for the use of TNF α . Hellman teaches that modulation of self proteins responsible for manifestations of a particular disease can be achieved using self-protein conjugated to a carrier which is recognized by T helper cells(see pages 5-12). The specification discloses that the role of TNF α in the pathogenesis of various diseases is known in the art (page 18, last paragraph). It would have been prima facies obvious to one of ordinary skill in the art at the time the invention was made to have created the claimed invention because the role of TNF α was known in the art and Hellman teaches that modulation of self proteins responsible for manifestations of a particular disease can be achieved using self molecules that contain T helper epitopes. The recitation of an intended method of use in these product claims carries no patentable weight.

24. No claim is allowed.

25. This application is a FWC of applicant's earlier Application No. 08/477501. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for response to this final action is set to expire **THREE MONTHS** from the date of this action. In the event a first response is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event will the statutory period for response expire later than **SIX MONTHS** from the date of this final action.

26. Papers related to this application may be submitted to Group 180 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Papers should be faxed to Group 180 at (703) 305-

Serial No. 08/803321

7

Art Unit 1816

7939.

27. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Ron Schwadron whose telephone number is (703) 308-4680. The examiner can normally be reached Tuesday through Friday from 8:30 to 6:00.

The examiner can also be reached on alternative Mondays. A message may be left on the examiners voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ms. Christina Chan can be reached on (703) 308-3973. Any inquiry of a general nature or relating to the status of this application should be directed to the Group 180 receptionist whose telephone number is (703) 308-0196.



**RONALD B. SCHWADRON
PRIMARY EXAMINER
GROUP 1800**

Ron Schwadron, Ph.D.

Primary Examiner

Art Unit 1816

April 17, 1997